Research database
SVF Research Library
Search 52,792 real PubMed studies on SVF and adipose-derived stem cells — 21 matching records.
21 results — page 1 of 1
- Level CProspective StudyPubMed
Integrated RNA sequencing and in vivo biosensor imaging define the early pathogenic cascade of Duchenne muscular dystrophy.
Prospective Study on Chronic Inflammation, published in Transl Res (2026) — summary generated from the PubMed abstract.
- 2026
Transl Res - Level DAnimal StudyPubMed
Continuous adipose-derived stem cell therapy from the neonatal stage effectively reduces Duchenne muscular dystrophy symptoms in rats.
Animal Study, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level CProspective StudyEurope PMC
Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy
Prospective Study, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci - Level DAnimal StudyPubMed
Sphingosine Phosphate Lyase Is Upregulated in Duchenne Muscular Dystrophy, and Its Inhibition Early in Life Attenuates Inflammation and Dystrophy in Mdx Mice.
Animal Study on Systemic / IV, published in Int J Mol Sci (2022) — summary generated from the PubMed abstract.
- 2022
Int J Mol Sci - Level DAnimal StudyPubMed
In utero transplantation of myoblasts and adipose-derived mesenchymal stem cells to murine models of Duchenne muscular dystrophy does not lead to engraftment and frequently results in fetal death.
Animal Study, published in Regen Ther (2022) — summary generated from the PubMed abstract.
- 2022
Regen Ther4 citations - Level DLaboratory StudyPubMed
The FibromiR miR-214-3p Is Upregulated in Duchenne Muscular Dystrophy and Promotes Differentiation of Human Fibro-Adipogenic Muscle Progenitors.
Laboratory Study, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
Cells - Level ASystematic ReviewEurope PMC
The Efficacy of Naïve versus Modified Mesenchymal Stem Cells in Improving Muscle Function in Duchenne Muscular Dystrophy: A Systematic Review
Systematic Review on Cardiovascular Disease, published in Biomedicines (2021) — summary generated from the PubMed abstract.
- 2021
Biomedicines7 citations - Level DAnimal StudyPubMed
Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy.
Animal Study, published in Biomolecules (2021) — summary generated from the PubMed abstract.
- 2021
Biomolecules - Level CCase Report / SeriesEurope PMC
Co-Transplantation of Bone Marrow-MSCs and Myogenic Stem/Progenitor Cells from Adult Donors Improves Muscle Function of Patients with Duchenne Muscular Dystrophy
Case Report / Series on Immune Modulation, published in Cells (2020) — summary generated from the PubMed abstract.
- 2020
Cells17 citations - Level DAnimal StudyEurope PMC
Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy
Animal Study on Hip, Systemic / IV, published in Biol Res (2020) — summary generated from the PubMed abstract.
- 2020
Biol Res14 citations - Level CProspective StudyPubMed
Can Wharton jelly derived or adipose tissue derived mesenchymal stem cell can be a treatment option for duchenne muscular dystrophy? Answers as transcriptomic aspect.
Prospective Study, published in Am J Stem Cells (2020) — summary generated from the PubMed abstract.
- 2020
Am J Stem Cells - Level DAnimal StudyPubMed
Beneficial role of adipose-derived mesenchymal stem cells from microfragmented fat in a murine model of duchenne muscular dystrophy.
Animal Study, published in Muscle Nerve (2019) — summary generated from the PubMed abstract.
- 2019
Muscle Nerve4 citations - Level CProspective StudyPubMed
Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.
Prospective Study on Cardiovascular Disease, published in Biomaterials (2018) — summary generated from the PubMed abstract.
- 2018
Biomaterials - Level DAnimal StudyPubMed
Metabolomic Analyses Reveal Extensive Progenitor Cell Deficiencies in a Mouse Model of Duchenne Muscular Dystrophy.
Animal Study, published in Metabolites (2018) — summary generated from the PubMed abstract.
- 2018
Metabolites - Level DLaboratory StudyPubMed
[Duchenne muscular dystrophy pathophysiology].
Laboratory Study, published in Arch Pediatr (2015) — summary generated from the PubMed abstract.
- 2015
Arch Pediatr - Level DNarrative ReviewPubMed
Skeletal muscle homeostasis in duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy.
Narrative Review on Cardiovascular Disease, published in Front Aging Neurosci (2014) — summary generated from the PubMed abstract.
- 2014
Front Aging Neurosci - Level BClinical TrialEurope PMC
Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy
Clinical Trial on Back & Spine, published in Ther Adv Neurol Disord (2013) — summary generated from the PubMed abstract.
- 2013
Ther Adv Neurol Disord20 citations - Level DNarrative ReviewEurope PMC
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies
Narrative Review on Cardiovascular Disease, published in Mamm Genome (2012) — summary generated from the PubMed abstract.
- 2012
Mamm Genome127 citations - Level DLaboratory StudyEurope PMC
Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysis
Laboratory Study, published in Neural Regen Res (2012) — summary generated from the PubMed abstract.
- 2012
Neural Regen Res3 citations - Level DNarrative ReviewEurope PMC
Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy
Narrative Review on Cardiovascular Disease, published in PM R (2009) — summary generated from the PubMed abstract.
- 2009
PM R28 citations - Level DAnimal StudyPubMed
[Mice adipose derived Flk-1+ mesenchymal stem cells can ameliorate Duchenne's muscular dystrophy in Mdx mice for their multilineage potential].
Animal Study, published in Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) — summary generated from the PubMed abstract.
- 2007
Zhongguo Shi Yan Xue Ye Xue Za Zhi1 citations
In-depth reviewed studies (full Thai translation)
Evidence system- Level ARandomized Controlled Trial
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial
A multicentre randomized trial in 480 knee osteoarthritis patients comparing SVF, BMAC and umbilical cord MSCs against corticosteroid injection. At 12 months no cell product outperformed the steroid control.
- 2023
- United States
- n = 480
- Level AMeta-analysis
Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials
Pooled five RCTs comparing ADSC/SVF injection with placebo or hyaluronic acid, finding significant pain and function improvement at 6 and 12 months.
- 2023
- South Korea
- Level AMeta-analysis
Rapid-acting pain relief in knee osteoarthritis: autologous-cultured adipose-derived mesenchymal stem cells outperform stromal vascular fraction: a systematic review and meta-analysis
Analysed 31 studies with 1,406 patients: cultured ADMSCs reduced pain from month 3, whereas SVF reached significance only at 12 months.
- 2024
- South Korea
- n = 1406